134 related articles for article (PubMed ID: 11472348)
1. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia.
Barosi G; Grossi A; Comotti B; Musto P; Gamba G; Marchetti M
Br J Haematol; 2001 Jul; 114(1):78-83. PubMed ID: 11472348
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies.
Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A
Leuk Lymphoma; 2002 Dec; 43(12):2301-7. PubMed ID: 12613516
[TBL] [Abstract][Full Text] [Related]
3. Thalidomide treatment in myelofibrosis with myeloid metaplasia.
Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt RM; Geyer SM; Tefferi A
Br J Haematol; 2002 May; 117(2):288-96. PubMed ID: 11972510
[TBL] [Abstract][Full Text] [Related]
4. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Thomas DA; Giles FJ; Albitar M; Cortes JE; Verstovsek S; Faderl S; O'Brien SM; Garcia-Manero G; Keating MJ; Pierce S; Zeldis J; Kantarjian HM
Cancer; 2006 May; 106(9):1974-84. PubMed ID: 16583431
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide in agnogenic and secondary myelofibrosis.
Canepa L; Ballerini F; Varaldo R; Quintino S; Reni L; Clavio M; Miglino M; Pierri I; Gobbi M
Br J Haematol; 2001 Nov; 115(2):313-5. PubMed ID: 11703326
[TBL] [Abstract][Full Text] [Related]
6. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
Marchetti M; Barosi G; Balestri F; Viarengo G; Gentili S; Barulli S; Demory JL; Ilariucci F; Volpe A; Bordessoule D; Grossi A; Le Bousse-Kerdiles MC; Caenazzo A; Pecci A; Falcone A; Broccia G; Bendotti C; Bauduer F; Buccisano F; Dupriez B
J Clin Oncol; 2004 Feb; 22(3):424-31. PubMed ID: 14752066
[TBL] [Abstract][Full Text] [Related]
7. Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia.
Mesa RA; Elliott MA; Schroeder G; Tefferi A
Mayo Clin Proc; 2004 Jul; 79(7):883-9. PubMed ID: 15244384
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study.
Piccaluga PP; Visani G; Pileri SA; Ascani S; Grafone T; Isidori A; Malagola M; Finelli C; Martinelli G; Ricci P; Baccarani M; Tura S
Leukemia; 2002 Sep; 16(9):1609-14. PubMed ID: 12200671
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.
Arora B; Mesa R; Tefferi A
Leuk Lymphoma; 2004 Dec; 45(12):2373-86. PubMed ID: 15621750
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide for the treatment of idiopathic myelofibrosis.
Strupp C; Germing U; Scherer A; Kündgen A; Mödder U; Gattermann N; Haas R
Eur J Haematol; 2004 Jan; 72(1):52-7. PubMed ID: 14962263
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.
Abgrall JF; Guibaud I; Bastie JN; Flesch M; Rossi JF; Lacotte-Thierry L; Boyer F; Casassus P; Slama B; Berthou C; Rodon P; Leporrier M; Villemagne B; Himberlin C; Ghomari K; Larosa F; Rollot F; Dugay J; Allard C; Maigre M; Isnard F; Zerbib R; Cauvin JM;
Haematologica; 2006 Aug; 91(8):1027-32. PubMed ID: 16885042
[TBL] [Abstract][Full Text] [Related]
12. Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia.
Merup M; Kutti J; Birgergård G; Mauritzson N; Björkholm M; Markevärn B; Maim C; Westin J; Palmblad J;
Med Oncol; 2002; 19(2):79-86. PubMed ID: 12180484
[TBL] [Abstract][Full Text] [Related]
13. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.
Mesa RA; Steensma DP; Pardanani A; Li CY; Elliott M; Kaufmann SH; Wiseman G; Gray LA; Schroeder G; Reeder T; Zeldis JB; Tefferi A
Blood; 2003 Apr; 101(7):2534-41. PubMed ID: 12517815
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Tefferi A; Cortes J; Verstovsek S; Mesa RA; Thomas D; Lasho TL; Hogan WJ; Litzow MR; Allred JB; Jones D; Byrne C; Zeldis JB; Ketterling RP; McClure RF; Giles F; Kantarjian HM
Blood; 2006 Aug; 108(4):1158-64. PubMed ID: 16609064
[TBL] [Abstract][Full Text] [Related]
15. Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly.
Berrebi A; Feldberg E; Spivak I; Shvidel L
Haematologica; 2007 Feb; 92(2):e15-6. PubMed ID: 17405746
[TBL] [Abstract][Full Text] [Related]
16. [Advances in thalidomide therapy for idiopathic myelofibrosis].
Song L; Chen JL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):651-3. PubMed ID: 19968089
[TBL] [Abstract][Full Text] [Related]
17. Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide.
Strupp C; Fenk R; Kündgen A; Gattermann N; Haas R; Germing U
Leuk Res; 2005 Aug; 29(8):967-9. PubMed ID: 15978949
[TBL] [Abstract][Full Text] [Related]
18. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia.
Tefferi A; Elliot MA
Blood; 2000 Dec; 96(12):4007. PubMed ID: 11186278
[No Abstract] [Full Text] [Related]
19. Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone.
Bělohlávková P; Maisnar V; Voglová J; Buchler T; Žák P
Acta Medica (Hradec Kralove); 2016; 59(2):50-3. PubMed ID: 27526305
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide treatment in a myelofibrosis patient with leukemia transformation.
Huang WH; Li MS; Chu SC; Wang TF; Kao RH; Wu YF
Int J Hematol; 2014 Feb; 99(2):188-92. PubMed ID: 24307514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]